Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

    Best Selling Products

    BioNewsCast Press Release Distribution Service

    BioNewsCast Press Release Distribution Service

     

    3rd Annual Stability Testing Conference

    3rd Annual Stability Testing Conference

     

    Next-Gen Sequencing Trends 2009

    Next-Gen Sequencing Trends 2009

     

    Competitor Analysis: c-MET/HGF Inhibitors

    Competitor Analysis: c-MET/HGF Inhibitors

     

    The Japanese Pharmaceutical Market 2008-2023

    The Japanese Pharmaceutical Market 2008-2023

     

    New Products

    Japanese Pharmaceutical Market 2009-2024

    Japanese Pharmaceutical Market 2009-2024

     

    3rd Annual Lyophilisation Conference

    3rd Annual Lyophilisation Conference

     

    The Global Bioinformatics Market: Market size, forecasts and company profiles

    The Global Bioinformatics Market: Market size, forecasts and company profiles

     

    Pharmaceutical Mergers and Acquisitions (PH133)

    Pharmaceutical Mergers and Acquisitions (PH133)

     

    Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

    Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

     

    Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

    Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

     

    The Global Analgesics Market 2009-2024

    The Global Analgesics Market 2009-2024

     

    Competitor Analysis: Coagulation Factors

    Competitor Analysis: Coagulation Factors

     

    Competitor Analysis: PDGF-R Agonists and Antagonists

    Competitor Analysis: PDGF-R Agonists and Antagonists

     

    World Market for Addiction Disorders, 2009-2016

    World Market for Addiction Disorders, 2009-2016

     

    BioPortfolio | Business Insights |  Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment

    Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment

    Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment


    As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which is forecast to value in excess of $135 billion by 2011. In response, the originators of biopharmaceutical products are resorting to a range of defensive tactics, including the reformulation of existing products to improve efficacy, the implementation of more efficient delivery systems and the pursuit of intellectual property battles. 'Negotiating the Emerging Biosimilars Landscape' is a new report published by Business Insights that examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the biosimilar market. The key factors affecting market access within the biosimilars market are assessed and the latest issues surrounding bioequivalence are examined. This report also provides a comprehensive review of the current legislative and regulatory positions of key geographic regions in addition to evaluating their anticipated future legislative changes and outcomes.

    Published: February 2009 - Global.
    Table of Contents
    Price: $3,835.00 / €2,565.62



    BioPortfolio uses RBS Worldpay Secure Server for credit card transactions